US2003216316A1PendingUtilityA1

Pharmaceutical compositions comprising erythropoietin for treatment of cancer

Assignee: YEDA RES & DEVPriority: Apr 8, 1998Filed: Mar 5, 2003Published: Nov 20, 2003
Est. expiryApr 8, 2018(expired)· nominal 20-yr term from priority
A61P 35/02A61K 38/1816A61P 35/00
37
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Pharmaceutical compositions comprising erythropoietin are provided for treatment of cancer, particularly for treatment of multiple myeloma. Erythropoietin was found to be effective for inhibition of tumor growth, triggering of tumor regression, stimulation of the natural immunological defense against cancer and/or inhibition of cancer cell metastasis.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for treatment of a multiple myeloma patient, comprising administering to said patient an amount of erythropoietin effective, and in a protocol effective, for stimulation of the natural immunological defense against multiple myeloma in said patient, wherein said amount and protocol are such that the administration continues for a sufficient time to result in said stimulation of the natural immunological defense against multiple myeloma in said patient.  
     
     
         2 . The method according to  claim 1  wherein the erythropoietin is recombinant human erythropoietin.

Join the waitlist — get patent alerts

Track US2003216316A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.